A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

NCT07276399 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Squamous Cell Carcinoma of Head and Neck

Interventions

BIOLOGICAL: Amivantamab
BIOLOGICAL: Pembrolizumab
DRUG: Carboplatin
DRUG: 5-Flurouracil
DRUG: Cisplatin

Sponsor

Janssen Research & Development, LLC